At a glance
- Originator Janssen-Cilag; Johnson & Johnson
- Developer Janssen-Cilag
- Class Anxiolytics
- Mechanism of Action Serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 25 Sep 2006 Discontinued - Preclinical for Anxiety disorders in Spain (unspecified route)
- 17 Sep 2002 Preclinical trials in Anxiety disorders in Spain (unspecified route)